The 184 references in paper I. Panina Yu., A. Rumyantsev Sh., M. Menshutina A., V. Achkasova V., O. Degtereva A., F. Tugusheva A., I. Zubina M., И. Панина Ю., А. Румянцев Ш., М. Меншутина А., В. Ачкасова В., О. Дегтерева А., Ф. Тугушева А., И. Зубин М. (2007) “ОСОБЕННОСТИ ФУНКЦИИ ЭНДОТЕЛИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ ДАННЫЕ // SPECIFIC FUNCTIONS OF THE ENDOTHELIUM IN CHRONIC KIDNEY DISEASE. LITERATURE REVIEW AND PERSONAL DATA” / spz:neicon:nefr:y:2007:i:4:p:28-46

1
Davies MJ, Thomas АС. Plaque fissuring - the cause of acute myocardial infarction, sudden ischem ic death, and creshendo angina. Brit Heart Jourrn 1985; 53: 363-373
(check this in PDF content)
2
Fuster V, Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 90: 2126-2146
(check this in PDF content)
3
Falk E, Shah PK, Faster V. Coronary plaque disruption. Circulation 1995; 92: 657-671
(check this in PDF content)
4
Петрищев НН. Современные аспекты эндотелиопро- текции в клинической практике. Ангиопротекция в практике терапевта: Материалы III Конгресса терапевтов Санкт-Пе­ тербурга и Северо-Западного Федерального округа Рос­ сии. СПб., 2004; 3-6
(check this in PDF content)
5
Петрищев НН, Власов ТД. Физиология и патофизио­ логия эндотелия. В: Петрищев НН, ред. Дисфункция эндо­ телия. Причины, механизмы, фармакологическая коррекция. Изд-во СПбГМУ, СПб., 2003; 4-38
(check this in PDF content)
6
Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321
(check this in PDF content)
7
Шишкин АН, Кирилюк ДВ. Дисфункция эндотелия у пациентов с прогрессирующ ими заболеваниями почек. Нефрология 2005; 9(2): 16-22
(check this in PDF content)
8
Noguera A, Busquets X, Sauleda J et al. Expression of adhesion molecules and G proteins in circulating neut trophils in chronic pulmonary disease. Am J Crit Care Med 1998; 158(5): 1664-1668
(check this in PDF content)
9
Гомазков ОА. Пептиды в кардиологии. Биохимия. Физиология. Патология. Информация. Анализ. Материк Альфа, М., 2000; 143
(check this in PDF content)
10
Дедов ИИ, Шестакова МВ, Кочемасова ТВ и др. Дис­ функция эндотелия в развитии сосудистых осложнений сахарного диабета. Рос физиол журн им И.М. Сеченова 2001; 87(8): 1073-1084
(check this in PDF content)
11
Shirahase H, Fujiwara M, Usui H, Kurahashi K. A possible role of thromboxane A2 in endothelium in maintaining resting tone and producing contractile response to acetylcholine and arachidonic acid in canine cerebral artery. Blood Vessels 1987; 24: 117-119
(check this in PDF content)
12
Kato T, Iwama Y, Okumura K et al. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990; 15: 475-482
(check this in PDF content)
13
Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis. J Invest Dermatol 2002; 119(6): 1379-1385
(check this in PDF content)
14
Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809-1819
(check this in PDF content)
15
Forstermann U, Biossel JP, Kleinert H. Expressional control of the constitutive isofiorms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773-790
(check this in PDF content)
16
Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 90: 244-254
(check this in PDF content)
17
Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-143
(check this in PDF content)
18
Манухина ЕБ, Смирин БВ, Малышев ИЮ и др. Депо­ нирование оксида азота в сердечно-сосудистой системе. Известия РАН. Серия биологическая 2002; 3
(check this in PDF content)
19
Onda Т, Mashiko S, Hamano M et al. Enhancement of endothelium-dependent relaxation in the aorta from stroke- prone spontaneously hypertensive rats at developmental stages of hypertension. Clin Exp Pharm Physiol 1994; 2i: 857-863
(check this in PDF content)
20
Liischer TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens 1994; 12 [suppl 10]: S105- S116
(check this in PDF content)
21
Wever RMF, Liischer TF, Consentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112
(check this in PDF content)
22
Muijsers RBR, Folkets G, Henricks PAJ et al. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997; 60: 1833-1845
(check this in PDF content)
23
Ванин АФ, Манухина ЕБ, Лапшин АВ, Меерсон ФЗ. Усиление синтеза оксида азота в стенке аорты при экспе­ риментальном инфаркте миокарда. Бюл экспер биол 1993; 116(8): 142-144
(check this in PDF content)
24
Манухина ЕБ, Покидышев ДА, Маленюк ЕБ и др. За­ щитный эффект окиси азота при тепловом шоке. Известия РАН. Серия биологическая 1997; 1: 54-58
(check this in PDF content)
25
Стокле Ж-К, Мюлле Б, Андрианцитохайна Р, Клещев А. Гиперпродукция оксида азота в патофизиологии крове­ носных сосудов. Биохимия 1998; 63 (7): 976-983
(check this in PDF content)
26
Star RA. Nitric oxide: Southwestern Internal Medicine Conference. Am J Med Soc 1993; 306: 348-355
(check this in PDF content)
27
Koch MA, Hasser EM, Schadt JC. Influence of nitric oxide on the hemodynamic response to hemorrhage in conscious rabbits. Am J Physiol 1995; 37: R171-R182
(check this in PDF content)
28
Mitsuhara H, Takeuchi H, Saitoh J et al. An inhibitor of nitric oxide synthase, N(omega)-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 1995; 3: 447-453
(check this in PDF content)
29
Arnal J-F, Dinh-Xuan A-T, Pueyo M et al. Endothelium- derived nitric oxide and vascular physiology. Cell Mol Life 1999; 55: 1078-1087
(check this in PDF content)
30
Abrahamsson Т, Brandt U, Marklund SL et al. Vascular bound recombinant extracellular superoxide dismutase type С protect against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation. Circulat Res 1992; 70: 264-271
(check this in PDF content)
31
Pagano PJ, Tornheim K, Cohen RA. Superoxide anion production by the rabbit thoracic aorta: Effect of endothelium- derived nitric oxide. Am J Physiol 1993; 265: H707-H712
(check this in PDF content)
32
Cohen RA. The role of nitric oxide and other endothelium- derived vasoactive substances in vascular disease. Progr Cardio-Vasc Dis I995; 38: 105-128
(check this in PDF content)
33
Feliciano L, Henning RJ. Coronary artery blood flow: physiologic and pathophysiologic regulation. Clin Cardiol 1999; 22: 775-786
(check this in PDF content)
34
Galle J, Bauersachs J, Bassenge E, Busse R. Arterial size determines the enhancement of contractile responses after suppression of endothelium-derived relaxing factor formation. Pflugers Arch 1993; 422: 564-569
(check this in PDF content)
35
Lozano G, Pagliaro P, Gatullo D, Marsh NA. Control of coronary blood flow by endothelial release of nitric oxide. Clin Exp Pharmacol Physiol 1994; 21: 783-789
(check this in PDF content)
36
Levin ER. Endothelins. N Engl J Med 1995; 323: 356­ 363
(check this in PDF content)
37
Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart synpathetic nerves. Circulat Res 1995; 77: 841-848
(check this in PDF content)
38
Hare J, Colluci WS. Role of nitric oxide in the regulation of myocardial function. Progr Cardiovasc Res 1995; 28: 155-166
(check this in PDF content)
39
Lewis MJ, Shah AM. Endothelial m odulation of myocardial contraction. Endothelium 1994; 1: 237-243
(check this in PDF content)
40
Welch G, Loscalzo J. Nitric oxide and cardiovascular system. J Cardiovasc Surg 1994; 9: 361-371
(check this in PDF content)
41
Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43: 580-594
(check this in PDF content)
42
Han X, Shimoni Y, Giles WR. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 1994; 476: 309-314
(check this in PDF content)
43
Minami N, Imai Y, Nishiyama H, Abe K. Role of nitric oxide in the developm ent of vascular a1-adrenoreceptor desensitization and pressure diuresis in conscious rats. Hypertension 1997; 29: 969-975
(check this in PDF content)
44
Tolins IP, Raij R. Role of endothelium-derived relaxing factor in hemodynamic response to acetylcholine in vivo. In: Nitric oxide from L-arginin: a bioregulatory system. Royal Society, London, 1989; 13
(check this in PDF content)
45
Thiemerman C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lypopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595
(check this in PDF content)
46
Gardiner SM, Compton AM, Bennett T et al. Control of regional blood flow by endothelium -derived nitric oxide. Hypertension 1990; 15: 486-492
(check this in PDF content)
47
Zatz R, Baylis С. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-964
(check this in PDF content)
48
Gerova M. Nitric oxide compromised hypertension: facts and enigmas. Physiol Res 2000; 49: 27-35
(check this in PDF content)
49
Baylis C, Mitruka В, Deng A. Chronic blockade of nitric oxide synthesis in the rat produced systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281
(check this in PDF content)
50
Chatziantoniou C, Boffa J, Ardaillou R, Dussaule J. Nitric oxide inhibition and early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. J Clin Invest 1998; 101: 2780-2789
(check this in PDF content)
51
Sessa WC, Pritchard K, Seyedi N et al. Chronic exercise in dog increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circulat Res 1994; 74: 349-353
(check this in PDF content)
52
Koller A, Kaley G. Shear stress dependent regulation of vascular resistance in health and disease: role of endothelium. Endothelium 1996; 4: 247-272
(check this in PDF content)
53
Celermajer DS, Sorensen KE, Gooch VM et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111­ 1115
(check this in PDF content)
54
Panza JA, Casino PR, Kilcoyne СМ, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium- dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468-1474
(check this in PDF content)
55
Antony I, Lerebours G, Nitemberg A. Loss of flow- dependent coronary artery dilatation in patients with hypertension. Circulation 1995; 91: 1624-1628
(check this in PDF content)
56
Lind L, Sarabi M, Millgard J. Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. Clin Physiol 1998; 18: 81-87
(check this in PDF content)
57
Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Hypertension 1995; 25: 201-206
(check this in PDF content)
58
Panza JA, Quyyumi AA, Brush JEJr, Epstein SE. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27
(check this in PDF content)
59
Anderson WD, Klein JL, Manoukian SV. Coronary flow mediated dilation is preserved in hypertensive patients. J Am Coc Cardiol 1994; 23: 107A
(check this in PDF content)
60
Minor RI, Myers PR, Guerra R Jr et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-2116
(check this in PDF content)
61
Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hyper- cholesterolemic patients by L-arginine. Lancet 1991; 338: 1546­ 1550
(check this in PDF content)
62
Cardillo C, Kilcoyne СМ, Quyyumi AA et al. Selective defect in nitric oxide synthesis may explain the im paired endothelium -dependent vasodilatation in patients with essential hypertension. Circulation 1998; 97: 851-856
(check this in PDF content)
63
Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links. Am J Hum Genet 1999; 64: 673-677
(check this in PDF content)
64
Birnbaum Y, Fishbein MC, Luo H et al. Regional remodeling of atherosclerotic arteries: a major determinant of clinical manifestations of disease. J Am Coll Cardiol 1997; 30: 1149-1164
(check this in PDF content)
65
Nimaguchi K, Egashira K, Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957­ 962
(check this in PDF content)
66
Luvara G, Pueyo M, Philippe M et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998; 18: 1408-1416
(check this in PDF content)
67
Godecke A, Decking UK, Ding Z et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circulat Res 1998; 82: 186-194
(check this in PDF content)
68
Huang PL, Huang Z, Mashimo H et al Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242
(check this in PDF content)
69
Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232
(check this in PDF content)
70
Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139
(check this in PDF content)
71
Meeus F, Kourilsky O, Guerin AP et al. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int 2000; 58 [suppl 76]: 140-146
(check this in PDF content)
72
Morris STW, McMurray JJV, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremical resistance arteries. Kidney Int 2001; 60(3): 1077-1081
(check this in PDF content)
73
Bennet-Richards KJ, Kattenhorn M, Donald AE et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62(4): 1372­ 1377
(check this in PDF content)
74
Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int 2004; 8(2): 118-123
(check this in PDF content)
75
Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63 [suppl] 84: 80-85
(check this in PDF content)
76
Kazuhiro S. Expression and regulation of endothelial nitric oxide synthase. TCM 1997; 7(1): 28-37
(check this in PDF content)
77
Robert MF, Rabelink TJ. Atherosclerosis and two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108­ 112
(check this in PDF content)
78
Шебеко ВИ, Родионов ЮЯ. Дисфункция эндотелия при гиперхолестеринемии и атеросклерозе. Мед Новости 1997; (11): 12-17
(check this in PDF content)
79
Holvoet P. Endothelial dysfunction, oxidation of low- density lipoprotein and cardiovascular disease. Ther Apheresis and Dialysis 1999; 3(4): 287-292
(check this in PDF content)
80
Galle J, Schneider R, Heinloth A et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55(4): 1450-1456
(check this in PDF content)
81
Heermeir K, Schneider R, Heinloth A et al. Oxidative stress mediates apoptosis induced by oxidized low-density lipoprotein and oxidized lipoprotein(a). Kidney Int 1999; 56(4): 1310-1315
(check this in PDF content)
82
Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051
(check this in PDF content)
83
Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321
(check this in PDF content)
84
Noon JP, Walker BR, Hand MF, Webb HD. Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol 1998; 45 (6): 545-551
(check this in PDF content)
85
Creager MA, Cooke JP, Mendelsohn MP et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-234
(check this in PDF content)
86
Lu Q, Eriksson M, Jogestrand T et al. M icro- and macrocirculatory effects of apheresis in patients with familial hyperlipidemia. Ther Apheresis and Dialysis 2003; 7(1): 115­ 120
(check this in PDF content)
87
Freiman PC, M itchell GG, Heistad DD et al. Atherosclerosis im pairs endothelium -dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986; 58: 783-789
(check this in PDF content)
88
Harrison DG, Arm strong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811
(check this in PDF content)
89
Marchesi S, Lupattelli G, Siepi D et al. Oral L-arginine administration attenuates postprandial endothelial dysfunction in young healthy males. J Clin Pharm Ther 2001; 25(5): 343-349
(check this in PDF content)
90
Algotsson A. Serum lipids and lipoproteins are correlated to skin vessel reactivity in healthy women. J Interrn Med 1996; 239(2): 147-153
(check this in PDF content)
91
Harrison DG, Arm strong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811
(check this in PDF content)
92
Benzuly KH, Padgett RC, Kaul S et al. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810-1818
(check this in PDF content)
93
Srisawat S, Phivthong-Ingam L, Unchern S et al. Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits. Clin Exp Pharm Physiol 2003; 30 (5-6): 405-409
(check this in PDF content)
94
Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996; 271: 1424-1437
(check this in PDF content)
95
Sand C, Peters SLM, Pfaffendorf M et al. Effects of hypochlorite and hydrogen peroxide on cardiac autonomic receptors and vascular endothelial function. Clin Exp Pharm Physiol 2003; 30 (4): 249-255
(check this in PDF content)
96
M artinet W, De Meyer GRY, Herman AG, Kockx M. Reactive oxygen species induce RNA damage in human atherosclerosis. Eur J Clin Invest 2004; 34(5): 323-329
(check this in PDF content)
97
Баранова ЕИ, Большакова ОО. Клиническое значе­ ние гипергомоцистеинемии. Артериальная гипертензия 2004; 10(1): 12-15
(check this in PDF content)
98
Malinow MR. Hyperhomocysteinemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006
(check this in PDF content)
99
Stam pfer MJ, Malinow MR, W illett WC et al. A prospective study of plasma hom ocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877­ 881
(check this in PDF content)
100
Selhub J, Jacques PF, Boston AG et al. Association between plasma homocysteine concentrations and extracranial catotid-artery stenosis. N Engl J Med 1995; 332: 286-291
(check this in PDF content)
101
Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332: 328-329
(check this in PDF content)
102
Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277(22): 1775-1781
(check this in PDF content)
103
Tawacol A, Omland T, Gerhard M et al. Hyperhom ocyst(e)inem ia is associated with im paired endothelium dependent vasodilation in humans. Circulation 1997; 95: 1119-1121
(check this in PDF content)
104
Welch G, Loscalzo J. Homocysteine and atherosclerosis. New Engl J Med 1998; 338(15): 1042-1050
(check this in PDF content)
105
Wang XL, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146: 133-140
(check this in PDF content)
106
Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741
(check this in PDF content)
107
Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelial derived relaxing factor and related oxide of nitrogen. J Clin Invest 1993; 91: 308-318
(check this in PDF content)
108
Berg M, Boers GH, Franken DG et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-181
(check this in PDF content)
109
Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24-29
(check this in PDF content)
110
Woo KS, Chook P, Lolin YI et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544
(check this in PDF content)
111
Lambert J, van den Berg M, Steyn M et al. Familial hyperhom ocysteinaem ia and endothelium -dependent vasodilation and arterial distensibility of large arteries. Cardiovasc Res 1999; 42: 743-751
(check this in PDF content)
112
Шевченко ОП, Олефриенко ГА. Гипергомоцистеи- немия и ее клиническое значение. Лаборатория 2002; (1): 3-7
(check this in PDF content)
113
Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617
(check this in PDF content)
114
Berwanger CL, Jeremy JY, Stansby GD. Homocysteine and vascular disease. Br J Surg 1995; 82: 726-731
(check this in PDF content)
115
Celermajer DS, Sorenson KE, Ryalls M et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858
(check this in PDF content)
116
Upchurch GR, Welch G, Fabian A et al. Stimulation of endothelial nitric oxide production by hom ocysteine. Atherosclerosis 1997; 132: 177-185
(check this in PDF content)
117
Demuth K, Atger V, Borderie D et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem 1999; 263(2): 367-372
(check this in PDF content)
118
Emsley AM, Jeremy JY, Gomes GN et al. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol 1999; 126: 1034-1040
(check this in PDF content)
119
Zhang X, Li H, Jin H et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000;279:671-678
(check this in PDF content)
120
Weiss N, Heydrick SJ, Postea O et al. Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1455-1461
(check this in PDF content)
121
Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98(1): 5-7
(check this in PDF content)
122
Jia L, Furchgott RF. Inhibition by sulph-hydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther 1993; 267:371-378
(check this in PDF content)
123
Emsley A, Plane F, Angelini GD, Jeremy JY. Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 1997; 122: 47-53
(check this in PDF content)
124
Glyglewski RJ, Palmer RMJ, Moncada S. Superoxide anion plays a role in the breakdown of endothelium-derived relaxing factor. Nature 1986; 320: 454-456
(check this in PDF content)
125
Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factors. Am J Physiol 1986; 250: H822-H827
(check this in PDF content)
126
McAninly J, Williams DLH, Askew SC et al. Metal-ion catalysis in nitrosothiol (RSNO) decomposition. J Chem Soc Commun 1993; 23: 1758-1759
(check this in PDF content)
127
Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376
(check this in PDF content)
128
Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and m odification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103
(check this in PDF content)
129
Upchurch GR, Welch GN, Loscalzo J. Homocysteine, EDRF and endothelial function. J Nutr 1996; 126: 1290S-1294S
(check this in PDF content)
130
Welch G, Upchurch G, Loscalzo J. Hyperhomocysteinemia and atherothrombosis. Ann NY Acad Sci 1997; 811: 48-58
(check this in PDF content)
131
Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 243-254
(check this in PDF content)
132
Fu W, Dudman N, Perry M, Wang H. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161(1): 169-176
(check this in PDF content)
133
Perna AF, Ingrosso D, Lombardi C et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003; 63 [suppl 84]: S137-S140
(check this in PDF content)
134
Hucks D, Thuraisingam RC, Raftery MJ, Yaqoob MM. Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dism utase mimetic TEMPOL. Nephrol Dial Transplant 2004; 19(8): 1999­ 2005
(check this in PDF content)
135
Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular in end stage renal disease (SPACE): randomized placebo controlled trial. Lancet 2000; 356: 1213-1218
(check this in PDF content)
136
Tepel M, van der Giet M, Statz M et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end stage renal failure. Circulation 2003; 107: 992-994
(check this in PDF content)
137
Drunat S, Moati N, Paul JL. Homocysteine-induced decrease in endothelin-1 production is initiated at extracellular level and involves oxidative products. Eur J Biochem 2001; 268 (20): 5287-5291
(check this in PDF content)
138
Pathasarathy S. Oxidation of low-density lipoprotein by thiol com pounds leads to its recognition by acetyl LDL receptor. Biochem Biophys Acta 1987; 917: 337-340
(check this in PDF content)
139
Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18
(check this in PDF content)
140
Blom HJ. Lipid peroxidation and susceptibility of low- density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-154
(check this in PDF content)
141
Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low- density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 27: 319-324
(check this in PDF content)
142
Tawacol A, Forgione M, Stueblinger M et al. Homocysteine impairs coronary microvascular dilator function in humans. JACC 2002; 40(6): 1051-1058
(check this in PDF content)
143
Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345(22): 1593-1600
(check this in PDF content)
144
Dijk RA, Rauwerda JA, Steyn M et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo- controlled trial. Arterioscler Thromb Vasc Biol 2001; 21: 2072­ 2079
(check this in PDF content)
145
Toole JF, Malinow MR, Chambless LE et al. Lowering hom ocysteine in patients with ischem ic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575
(check this in PDF content)
146
Wrone EM, Hornberger JM, Zehnder J et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426
(check this in PDF content)
147
Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhom ocysteinaem ia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112
(check this in PDF content)
148
Austen SK, Coombes JS, Fassett RG. Homocysteine­ lowering therapy in renal disease. Clin Nephrol 2003; 60: 375­ 385
(check this in PDF content)
149
Vallance P, Leone A, Calver A et al. Endogenous dim ethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 [suppl 12]: S60-S62
(check this in PDF content)
150
Fickling SA, Leone AM, Nussey SS et al. Synthesis of NG, Ng dim ethylarginine by human endothelial cells. Endothelium 1993; 1: 137-140
(check this in PDF content)
151
Boger RH, Bode-Boger SM, Tsao PS et al. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherosclerotic effects in cultural human endothelial cells. Circulation 1997; 96; [suppl 1]: 1588
(check this in PDF content)
152
Bode-Boger SM, Boger RH, Kieke S et al. Elevated L- arginine/dim ethylarginine ratio contributes to enhanced system ic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603
(check this in PDF content)
153
Boger RH, Bode-Boger SM, Phivthong-Ingam L et al. Dietary L-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282-1290
(check this in PDF content)
154
Boger RH, Bode-Boger SM, Thiele W et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive. Circulation 1997; 95: 2068-2074
(check this in PDF content)
155
Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842­ 1847
(check this in PDF content)
156
Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617
(check this in PDF content)
157
Boger RH, Bode-Boger SM, Sydow K et al. Plasma concentration of asymmetric dymethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000: 20; 1557-1561
(check this in PDF content)
158
Hornig B, Bode-Boger SM, Arakawa N et al. Lack of im provem ent of hom ocyst(e)ine-induced endothelial dysfunction during supplementation with B vitamins in patients with arterial occlusive disease. Circulation 1999; 100 [suppl 1]: 757
(check this in PDF content)
159
Zoccali C, Mallamaci LS, Maas R et al. Left ventricular hypertrophy, cardiac rem odeling and asym m etric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62(1): 339-345
(check this in PDF content)
160
Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int 2003; 63 [suppl 84]: 37-43
(check this in PDF content)
161
Zoccali C, Mallamaci F, Tripepi G. Traditional and em erging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63 [suppl 85]: 105-111
(check this in PDF content)
162
Suliman ME, Stenvinkel P, Heimburger O et al. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002; 40: 480-488
(check this in PDF content)
163
Faraci FM, Orgren K, Heistad DD. Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys. Stroke 1994; 25: 178-182
(check this in PDF content)
164
Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373
(check this in PDF content)
165
Tang L, Mamotte CD, van Bockxmeer FM, Taylor RR. The effect homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-173
(check this in PDF content)
166
Hansrani M, Gillespie J, Stransby G. Homocysteine in myointimal hyperplasia. Eur J Vasc Endovasc Surg 2002; 23: 3­ 10
(check this in PDF content)
167
Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081
(check this in PDF content)
168
Noris M, Remuzzi G. Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Phys 1999; 111(6): 602-608
(check this in PDF content)
169
Benchetrit S, Green J, Katz D et al. Early endothelial dysfunction following renal mass reduction in rats. Eur J Clin Invest 2003; 33(1): 26-31
(check this in PDF content)
170
Asahi K, Ichimori K, Nakazawa H et al. Nitric oxide inhibits the formation of advanced end products. Kidney Int 2000; 58(4): 1780-1785
(check this in PDF content)
171
Stenvinkel P, Alvestrand A. Review Articles Inflamm ation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002; 15(5): 329­ 335
(check this in PDF content)
172
Ребров АП, Зелепукина НЮ. Дисфункция эндоте­ лия у больных хроническим гломерулонефритом в различ­ ных стадиях почечной недостаточности. Нефрология и диализ 2001; 3(4): 39-46
(check this in PDF content)
173
Watts GF, Herrmann S, Dogra GK et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60(1): 182-187
(check this in PDF content)
174
Dogra GK, Watts GF, Herrmann S et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002; 62 (2): 550-556
(check this in PDF content)
175
Hausberg M, Kisters K, Kosch M et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55(3):1104-1109
(check this in PDF content)
176
Asberg A, Holdaas H, Jardine AG et al. Fluvastatin reduces atherogenic lipids w ithout any effect on native endothelial function early after kidney transplantation. Clin Transplantation 2003; 17(4): 385-391
(check this in PDF content)
177
Paisley KE, Beaman M, Tooke JE et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63(2): 624-631
(check this in PDF content)
178
Hand MF, Haynes WG, Webb DJ. Hemodialysis and L- arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53(4): 1068-1073
(check this in PDF content)
179
London GM, Pannier B, Agharazii M et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004; 65(2): 700-705
(check this in PDF content)
180
Pannier B, Guerin AP, Marchais SJ et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end stage renal disease. Kidney Int 2000; 57(3): 1091-1097
(check this in PDF content)
181
Wang D, Iversen J, W ilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosom al-dom inant polycystic kidney disease. Kidney Int 2003; 64(4): 1381-1386
(check this in PDF content)
182
Al-Nimri MA, Komers R, Oyama TT et al. Endothelial- derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63(5):1776-1782
(check this in PDF content)
183
Oflaz H, Turkmen A, Kazancioglu R et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Tranplantation 2003; 17(3): 212-217
(check this in PDF content)
184
Annuk M, Zilmer M, Fellstrom B. Endothelium - dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int 2003; 63 [suppl 84]: 50-54 Поступила в редакцию 17.10.2007 г.
(check this in PDF content)